Immunotherapeutic Advancements for Glioblastoma

Frontiers in Oncology

Volumn 5, Issue , 2015, Pages

  Ampie, Leonel ^a   Woolf, Eric C ^a   Dardis, Christopher ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

antibodies; checkpoint modulators; glioblastoma; immunotherapy; monoclonal; T cell engineering; vaccines

Indexed keywords

EID: 85119044074     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00012     Document Type: Review

References (85)

1. Field KM Jordan JT Wen PY Rosenthal MA Reardon DA. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer (2014).10.1002/cncr.2893525263092
2. Hoption Cann SF Gunn HD van Netten JP. Spontaneous regression of pancreatic cancer. Case Rep Clin Pract Rev (2004) 5:293–6.
3. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J (2006) 26:154–8.16789469
4. Lebbe C Weber JS Maio M Neyns B Harmankaya K Hamid O et al. Survival follow-up and ipilimumab retreatment for patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol (2014) 25(11):2277–84.10.1093/annonc/mdu44125210016
5. Chakrabarty AM. Microorganisms and cancer: quest for a therapy. J Bacteriol (2003) 185:2683–6.10.1128/JB.185.9.2683-2686.2003
6. Chorobik P Czaplicki D Ossysek K Bereta J. Salmonella and cancer: from pathogens to therapeutics. Acta Biochim Pol (2013) 60:285–97.23828775
7. Lundstrom M. 2 UC Davis Neurosurgeons Accused of Experimental Surgery are Banned from Human Research. California, CA: Sacramento Bee (2012).
8. Kmiecik J Poli A Brons NH Waha A Eide GE Enger PO et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol (2013) 264:71–83.10.1016/j.jneuroim.2013.08.01324045166
9. Yue Q Zhang X Ye HX Wang Y Du ZG Yao Y et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol (2014) 116:251–9.10.1007/s11060-013-1314-024276989
10. Stupp R Mason WP van den Bent MJ Weller M Fisher B Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987–96.10.1056/NEJMoa04333015758009
11. Fonkem E Wong ET. NovoTTF-100A: a new treatment modality for recurrent glioblastoma. Expert Rev Neurother (2012) 12:895–9.10.1586/ern.12.8022708931
12. Ransohoff RM Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol (2012) 12:623–35.10.1038/nri326522903150
13. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol (2009) 9:429–39.10.1038/nri256519461673
14. Torres-Platas SG Comeau S Rachalski A Bo GD Cruceanu C Turecki G et al. Morphometric characterization of microglial phenotypes in human cerebral cortex. J Neuroinflammation (2014) 11:12.10.1186/1742-2094-11-1224447857
15. Hickey WF Hsu BL Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res (1991) 28:254–60.10.1002/jnr.490280213
16. Heimberger AB Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol (2011) 13:3–13.10.1093/neuonc/noq16921149252
17. Thomas AA Ernstoff MS Fadul CE. Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 18:59–68.10.1097/PPO.0b013e3182431a73
18. Vauleon E Avril T Collet B Mosser J Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol (2010) 2010:689171.10.1155/2010/68917120953324
19. Wilson EH Weninger W Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest (2010) 120:1368–79.10.1172/JCI4191120440079
20. Mehling M Simon P Mittelbronn M Meyermann R Ferrone S Weller M et al. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol (2007) 114:111–9.10.1007/s00401-007-0231-817541610
21. El Andaloussi A Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol (2006) 8:234–43.10.1215/15228517-2006-00616723631
22. Jacobs JF Idema AJ Bol KF Nierkens S Grauer OM Wesseling P et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol (2009) 11:394–402.10.1215/15228517-2008-10419028999
23. Zisakis A Piperi C Themistocleous MS Korkolopoulou P Boviatsis EI Sakas DE et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine (2007) 39:99–105.10.1016/j.cyto.2007.05.01217697783
24. Joseph JV Balasubramaniyan V Walenkamp A Kruyt FA. TGF-beta as a therapeutic target in high grade gliomas – promises and challenges. Biochem Pharmacol (2013) 85:478–85.10.1016/j.bcp.2012.11.00523159669
25. Learn CA Fecci PE Schmittling RJ Xie W Karikari I Mitchell DA et al. Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers. Clin Cancer Res (2006) 12:7306–15.10.1158/1078-0432.CCR-06-172717189402
26. Manzur M Hamzah J Ganss R. Modulation of the “blood-tumor” barrier improves immunotherapy. Cell Cycle (2008) 7:2452–5.10.4161/cc.7.16.645118719382
27. Ngiow SF Teng MW Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res (2011) 71:6567–71.10.1158/0008-5472.CAN-11-148722009533
28. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252–64.10.1038/nrc323922437870
29. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell (1992) 71:1065–8.10.1016/S0092-8674(05)80055-8
30. Rudd CE Taylor A Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev (2009) 229:12–26.10.1111/j.1600-065X.2009.00770.x19426212
31. Linsley PS Brady W Urnes M Grosmaire LS Damle NK Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 174:561–9.10.1084/jem.174.3.5611714933
32. Freeman GJ Gribben JG Boussiotis VA Ng JW Restivo VA Jr Lombard LA et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science (1993) 262:909–11.10.1126/science.76943637694363
33. Alegre ML Frauwirth KA Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol (2001) 1:220–8.10.1038/3510502411905831
34. Wing K Onishi Y Prieto-Martin P Yamaguchi T Miyara M Fehervari Z et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 322:271–5.10.1126/science.116006218845758
35. Peggs KS Quezada SA Chambers CA Korman AJ Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 206:1717–25.10.1084/jem.2008249219581407
36. Callahan MK Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 94:41–53.10.1189/jlb.1212631
37. Knisely JP Yu JB Flanigan J Sznol M Kluger HM Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 117:227–33.10.3171/2012.5.JNS11192922702482
38. Schaff LR Lassman AB Goldlust SA Cloughesy TF Singer S Schwartz GK et al. Ipilimumab for recurrent glioblastoma (GB). J Clin Oncol (2014) 32:e13026.
39. Hu JL Sharma P Yu J Black KL Rudnick JD. Ipilimumab for recurrent glioblastoma: a single-institution case series. J Clin Oncol (2014) 32:e13010.
40. Francisco LM Salinas VH Brown KE Vanguri VK Freeman GJ Kuchroo VK et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 206:3015–29.10.1084/jem.2009084720008522
41. Velu V Titanji K Zhu B Husain S Pladevega A Lai L et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature (2009) 458:206–10.10.1038/nature0766219078956
42. Wolchok JD Kluger H Callahan MK Postow MA Rizvi NA Lesokhin AM et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122–33.10.1056/NEJMoa130236923724867
43. Tumeh PC Harview CL Yearley JH Shintaku IP Taylor EJ Robert L et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515:568–71.10.1038/nature1395425428505
44. Dong H Strome SE Salomao DR Tamura H Hirano F Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 8:793–800.10.1038/nm73012091876
45. Parsa AT Waldron JS Panner A Crane CA Parney IF Barry JJ et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2007) 13:84–8.10.1038/nm151717159987
46. Powles T Eder JP Fine GD Braiteh FS Loriot Y Cruz C et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 515:558–62.10.1038/nature1390425428503
47. Herbst RS Soria JC Kowanetz M Fine GD Hamid O Gordon MS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 515:563–7.10.1038/nature1401125428504
48. Petrosiute A Auletta JJ Lazarus HM. Achieving graft-versus-tumor effect in brain tumor patients: from autologous progenitor cell transplant to active immunotherapy. Immunotherapy (2012) 4:1139–51.10.2217/imt.12.9623194364
49. Sayegh ET Oh T Fakurnejad S Bloch O Parsa AT. Vaccine therapies for patients with glioblastoma. J Neurooncol (2014) 119:531–46.10.1007/s11060-014-1502-625163836
50. Smaglo BG Aldeghaither D Weiner LM. The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 11(11):637–48.10.1038/nrclinonc.2014.15925265912
51. Neidert MC Schoor O Trautwein C Trautwein N Christ L Melms A et al. Natural HLA class I ligands from glioblastoma: extending the options for immunotherapy. J Neurooncol (2013) 111:285–94.10.1007/s11060-012-1028-823263746
52. Wong AJ Ruppert JM Bigner SH Grzeschik CH Humphrey PA Bigner DS et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A (1992) 89:2965–9.10.1073/pnas.89.7.2965
53. Heimberger AB Hlatky R Suki D Yang D Weinberg J Gilbert M et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res (2005) 11:1462–6.10.1158/1078-0432.CCR-04-173715746047
54. Sampson JH Heimberger AB Archer GE Aldape KD Friedman AH Friedman HS et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 28:4722–9.10.1200/JCO.2010.28.696320921459
55. Powers MV Jones K Barillari C Westwood I van Montfort RL Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle (2010) 9:1542–50.10.4161/cc.9.8.1120420372081
56. Young JC Agashe VR Siegers K Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol (2004) 5:781–91.10.1038/nrm149215459659
57. Crane CA Han SJ Ahn B Oehlke J Kivett V Fedoroff A et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res (2013) 19:205–14.10.1158/1078-0432.CCR-11-335822872572
58. Bloch O Crane CA Fuks Y Kaur R Aghi MK Berger MS et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2014) 16:274–9.10.1093/neuonc/not203
59. Jackson C Ruzevick J Brem H Lim M. Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy (2013) 5:155–67.10.2217/imt.12.15523413907
60. Schirrmacher V Haas C Bonifer R Ahlert T Gerhards R Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther (1999) 6:63–73.10.1038/sj.gt.330078710341877
61. Steiner HH Bonsanto MM Beckhove P Brysch M Geletneky K Ahmadi R et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol (2004) 22:4272–81.10.1200/JCO.2004.09.03815452186
62. Liu SQ Saijo K Todoroki T Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nat Med (1995) 1:267–71.10.1038/nm0395-2677585045
63. Liu SQ Shiraiwa H Kawai K Hayashi H Akaza H Kim BS et al. Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nat Med (1996) 2:1283.10.1038/nm1296-1283
64. Ohno T. Autologous formalin-fixed tumor vaccine. Curr Pharm Des (2005) 11:1181–8.10.2174/138161205350762015853665
65. Ohno T. Autologous cancer vaccine: a novel formulation. Microbiol Immunol (2003) 47:255–63.10.1111/j.1348-0421.2003.tb03393.x12801062
66. Muragaki Y Maruyama T Iseki H Tanaka M Shinohara C Takakura K et al. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. J Neurosurg (2011) 115:248–55.10.3171/2011.4.JNS10377
67. Tanaka S Louis DN Curry WT Batchelor TT Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2013) 10:14–26.10.1038/nrclinonc.2012.20423183634
68. Tse BW Jovanovic L Nelson CC De Souza P Power CA Russell PJ. From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int (2014) 2014:981434.10.1155/2014/98143425276838
69. Prins RM Soto H Konkankit V Odesa SK Eskin A Yong WH et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res (2011) 17:1603–15.10.1158/1078-0432.CCR-10-256321135147
70. Phuphanich S Wheeler CJ Rudnick JD Mazer M Wang H Nuno MA et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2013) 62:125–35.10.1007/s00262-012-1319-022847020
71. Cobbs CS Harkins L Samanta M Gillespie GY Bharara S King PH et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 62:3347–50.12067971
72. Scheurer ME Bondy ML Aldape KD Albrecht T El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 116:79–86.10.1007/s00401-008-0359-118351367
73. Dziurzynski K Chang SM Heimberger AB Kalejta RF McGregor Dallas SR Smit M et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol (2012) 14:246–55.10.1093/neuonc/nor22722319219
74. Landi D Hegde M Ahmed N. Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy. Front Oncol (2014) 4:338.10.3389/fonc.2014.0033825505736
75. Prins RM Cloughesy TF Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 359:539–41.10.1056/NEJMc0804818
76. Crough T Beagley L Smith C Jones L Walker DG Khanna R. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell Biol (2012) 90:872–80.10.1038/icb.2012.1922508289
77. Schuessler A Smith C Beagley L Boyle GM Rehan S Matthews K et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res (2014) 74:3466–76.10.1158/0008-5472.CAN-14-029624795429
78. Weller M Soffietti R Brada M. The legend of cytomegalovirus and glioblastoma lives on. Neuro Oncol (2014) 16:166.10.1093/neuonc/not204
79. Eshhar Z Waks T Gross G Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A (1993) 90:720–4.10.1073/pnas.90.2.720
80. Ahmed N Salsman VS Kew Y Shaffer D Powell S Zhang YJ et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res (2010) 16:474–85.10.1158/1078-0432.CCR-09-132220068073
81. Miao H Choi BD Suryadevara CM Sanchez-Perez L Yang S De Leon G et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One (2014) 9(4):e94281.10.1371/journal.pone.009428124722266
82. Bullain SS Sahin A Szentirmai O Sanchez C Lin N Baratta E et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol (2009) 94:373–82.10.1007/s11060-009-9889-119387557
83. Maki RG Livingston PO Lewis JJ Janetzki S Klimstra D Desantis D et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci (2007) 52:1964–72.10.1007/s10620-006-9205-217420942
84. Agarwalla P Barnard Z Fecci P Dranoff G Curry WT Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother (2012) 35:385–9.10.1097/CJI.0b013e3182562d59
85. Bozic I Reiter JG Allen B Antal T Chatterjee K Shah P et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 25(2):e00747.10.7554/eLife.0074723805382